Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» BioXcel Therapeutics
BioXcel Therapeutics
Major readouts on the horizon for small developers
Major readouts on the horizon for small developers
EP Vantage
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
Flag link:
BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop
BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop
Fierce Biotech
BioXcel Therapeutics
clinical trials
Keytruda
BXCL701
prostate cancer
Flag link:
Catalysts ahead for the smaller players
Catalysts ahead for the smaller players
EP Vantage
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
Flag link:
11 drugs granted FDA fast track designation in 2022
11 drugs granted FDA fast track designation in 2022
Beckers Hospital Review
FDA
fast track
Agios Pharmaceuticals
CTI BioPharma
Bristol Myers Squibb
Nobel Biocare
BioXcel Therapeutics
Mycovia Pharmaceuticals
Phathom Pharmaceuticals
Mitsubishi Tanabe Pharma
SIGA technologies
Alnylam Pharmaceuticals
Flag link:
